Press Releases

Memorial Sloan Kettering Cancer Center (MSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (COTELLIC®) for the treatment of adult patients with the family of blood diseases know as histiocytic neoplasms (HN). These diseases include: Erdheim-Chester Disease, Rosai-Dorfman, and Langerhans Histiocytosis. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma.

Carol Morris, MD, MS, has assumed the position of Chief of the Orthopaedic Surgery Service at Memorial Sloan Kettering Cancer Center (MSK).

Memorial Sloan Kettering Cancer Center (MSK) today announced that it has been awarded a Specialized Programs of Research Excellence (SPORE) grant for pancreatic research by the National Cancer Institute (NCI).

Sloan Kettering Institute’s (SKI) Alexander Gitlin, MD, PhD of Memorial Sloan Kettering Cancer Center (MSK) was recognized as a winner of the National Institutes of Health (NIH) Director’s Early Independence Award.

The funding will support patient navigation, essential needs, telemedicine, and psychosocial support services, including language translation and interpretation.

Memorial Sloan Kettering Cancer Center (MSK) today announced that Selwyn M. Vickers, MD, FACS, an internationally recognized pancreatic cancer surgeon and researcher, a pioneer in cancer health disparities research, and an academic medical leader, has joined the institution as President and Chief Executive Officer.